Beefing up Prostate Cancer Therapy with Performance

In the May 26th issue of the New England Journal of Medicine, de Bono et al. report that the inhibition of androgen synthesis by abiraterone acetate prolonged the survival of men with prostate cancer previously treated by androgen suppression.

Androgen suppression acts as targeted therapy for prostate cancer therefore, at least in part by suppressing the transcription of fusion oncogenes. For many years, the propensity for prostate cancer to progress despite androgen suppression was attributed to the emergence of "androgen-independent" prostate cancer cell clones.
Beefing up Prostate Cancer Therapy with Performance

Request PDF | Beefing up Prostate Cancer Therapy with Performance-Enhancing ( Anti -) Steroids | In the May 26th issue of the New England Journal of Medicine, de Bono et al. report that the ...
It is proposed that, in hormone-dependent tumors like breast and prostate cancers , a hormone-cycling therapy , in combination with topoisomerase II poisons or inhibitors of the DNA repair components PARP1 and DNA-PK, could overwhelm cancer cells with transcription-associated DSBs.

Beefing up Prostate Cancer Therapy with Performance
Genet. 43, 309-315. Beefing up Prostate Cancer Therapywith Performance-Enhancing ( Anti -) SteroidsWilliam G. Nelson, 1, * Michael C. Haffner, 1 and Srinivasan Yegnasubramanian 1, *1 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 400 North Broadway Street, Baltimore, MD21231-1000, USA*Correspondence ...
Home Publicaties Beefing up prostate cancer therapy with performance-enhancing ( anti -) steroids. Beefing up prostate cancer therapy with performance-enhancing ( anti -) steroids.

Beefing up Prostate Cancer Therapy with Performance
Article " Beefing up Prostate Cancer Therapy with Performance-Enhancing ( Anti -) Steroids" Detailed information of the J-GLOBAL is an information service managed by the Japan Science and Technology Agency (hereinafter referred to as "JST"). It provides free access to secondary information on researchers, articles, patents, etc., in science and technology, medicine and pharmacy. The search ...
ASCO 2026, metastatic castration resistant prostate cancer (mCRPC), Tambotatug pelitecan, YL201, anti -B7H3 antibody-drug conjugate, B7-H3-targeted therapy .

PARP and Androgen
Patients with metastatic APMS prostate cancer could have received up to 3 months of androgen-deprivation therapy with or without an approved androgen-receptor pathway inhibitor.







This collaborative review outlines emerging strategies for treating prostate cancer by reporting the most up -to-date results from international on-going trials.